Premapping commanded electrogram parameters and 3-month atrial pacing threshold after atrial leadless pacemaker implantation Authors: Yohei Kikuchi, Keita Yoshiyama, Daiki Kumazawa, Kosuke Onodera, Yosuke Mizuno, Masato Munehisa, Kennosuke Yamashita Published: 2026 Key Findings ▪Premapping atrial pacing threshold was associated with 3-month atrial capture threshold after Aveir AR implantation, but this signal is confounded by operator-driven site selection and is not an independent predictor. Premapping atrial pacing threshold was associated with 3-month atrial capture threshold after Aveir AR implantation, but this signal is confounded by operator-driven site selection and is not an independent predictor. ▪Waveform-derived commanded electrogram parameters (amplitude, current of injury, first derivative of voltage over time) did not discriminate chronic threshold and showed only hypothesis-generating tendencies, without incremental value over premapping threshold. Waveform-derived commanded electrogram parameters (amplitude, current of injury, first derivative of voltage over time) did not discriminate chronic threshold and showed only hypothesis-generating tendencies, without incremental value over premapping threshold. ▪Atrial-specific tissue and anchoring features limit direct extrapolation of ventricular leadless pacing predictors, supporting the need for prospective, atrial-targeted procedural markers. Atrial-specific tissue and anchoring features limit direct extrapolation of ventricular leadless pacing predictors, supporting the need for prospective, atrial-targeted procedural markers. Introduction Leadless pacing has progressed from ventricular-only systems to atrial and dual-chamber platforms, shifting attention from procedural feasibility to optimization of implant-site selection.1, 2, 3, 4, 5 In ventricular leadless pacing, intraprocedural impedance, current of injury (COI), and electrogram characteristics have been linked to later pacing performance.6,7 Whether the same signals are informative for atrial leadless pacing is uncertain because the atrium differs from the ventricle in wall thickness, tissue architecture, chamber mechanics, and substrate remodeling.5,8,9 In addition, the Aveir AR helix-fixation system relies on engagement with comparatively thin atrial myocardium, and elderly candidates frequently exhibit atrial cardiomyopathy with fibrosis and chamber enlargement; these atrial-specific features may attenuate the predictive value of intraprocedural electrical signals derived from ventricular leadless pacing experience. Therefore, we examined whether premapping commanded electrogram (cEGM) parameters are associated with 3-month atrial pacing performance after Aveir AR implantation, with all analyses prespecified as exploratory and hypothesis generating because of the small single-center sample size. Methods The research reported in this manuscript adhered to the principles of the Declaration of Helsinki and was approved by the institutional review board of Sendai Kosei Hospital (approval number: 7-46). Because this was a retrospective observational study, an opt-out appoach was used in lieu of a written informed consent; patients were notified of the study through a public posting at the institution and were given the opportunity to decline participation, and all patient data were deidentified before analysis. We retrospectively studied 39 consecutive patients who underwent leadless atrial pacemaker implantation at Sendai Kosei Hospital between February and September 2025. 37 patients underwent dual-chamber implantation, and 2 underwent standalone atrial implantation. The primary endpoint was atrial pacing capture threshold (PCT) at 3 months. Patients were categorized into a favorable PCT group (≤0.5 V at 0.4 ms) and an elevated PCT group (>0.5 V). Premapping variables included impedance, sensing amplitude, pacing threshold, cEGM amplitude, COI, cEGM duration, and the values of first derivative of voltage over time (dV/dt) for the R, S, and J waves (dV/dt-R, dV/dt-S, and dV/dt-J). Programmer-exported waveforms were calibrated using the displayed time and voltage scales. Signal amplitude was defined as the difference between baseline and the atrial R-wave peak, cEGM duration from initial deflection to the J point, and COI as J-point elevation (Figure 1). For slope analysis, cEGMs were digitized into time-voltage series, and first-derivative values were computed using a prespecified finite-difference script. For each waveform component, the representative dV/dt value was defined as the peak slope of the corresponding deflection. For the R wave, this was defined as the peak positive dV/dt. All tracings were reviewed according to predefined rules by 2 electrophysiologists (Y.K. and K. Y.). Because of the small sample size, analyses were considered exploratory and intended to identify candidate procedural markers rather than definitive clinical cut points. Categorical variables were presented in frequency tables and compared using Pearson’s χ2 test if all cell sizes were >5 or Fisher’s exact test if otherwise. Continuous variables are expressed as medians with interquartile ranges and compared using the Mann-Whitney U test and the Wilcoxon signed-rank test. All statistical tests were 2 tailed. P < .05 was considered statistically significant. Receiver operating characteristic analysis was performed to identify predictors of elevated PCT at 3 months. JMP 17.0.0 software (SAS Institute Inc, Cary, NC) was used for all analyses. Measurement of premapping commanded electrogram (cEGM) parameters. A: Definitions of cEGM amplitude, current of injury, cEGM duration, and R-wave first derivative of voltage over time measured from premapping commanded electrograms. Measurements were evaluated at premap, postfixation (tether mode), and postdeployment. Results 32 of 39 patients (82.1%) had a favorable 3-month PCT, and 7 (17.9%) had an elevated 3-month PCT; baseline patient characteristics are presented in Supplemental Table 1. In the primary 2-group comparison, premapping PCT was lower in the favorable PCT group (2.5 V [1.9–3.0] vs 3.2 V [2.9–4.2]; P = .026); however, this association should be interpreted with caution because the premapping threshold itself directly informed the operator’s decision to deploy or obtain an additional premap, introducing a potential operator-selection bias rather than reflecting an independent intrinsic tissue property. None of the other premapping electrical parameters, including impedance, sensing, cEGM amplitude, COI, the waveform-derived dV/dt indices (dV/dt-R, dV/dt-S, dV/dt-J), cEGM duration, or Δ impedance, differed significantly between the 2 groups (Table 1); given the limited sample size and statistical power, these nonsignificant results should not be interpreted as the absence of association. Right atrial enlargement and tricuspid regurgitation were more common in patients with higher chronic thresholds (Table 1). Longitudinally, patients in the favorable PCT group showed persistently lower PCT values from implantation through follow-up, whereas those in the elevated PCT group maintained higher thresholds over time (Figure 2). In exploratory, hypothesis-generating analyses, sharper premapping waveforms and larger premapping amplitudes appeared to track with extreme chronic phenotypes (Supplemental Table 2): higher dV/dt-R and larger cEGM amplitude tended to occur in patients with very low chronic thresholds, whereas low premapping amplitude and low postfixation COI tended to occur in patients with elevated chronic thresholds. These observations are presented as illustrative reference values rather than as validated clinical thresholds and were not shown to provide demonstrable incremental value beyond the premapping threshold in this small cohort (Figure 3). Table 1Procedural and premapping electrical parameters according to 3-month atrial pacing thresholdParameterFavorable PCT group (≤0.5 V) (n = 32)Elevated PCT group (>0.5 V) (n = 7)P valueProcedural dataProcedural time (min)50.0 [41.0–60.0]55.0 [37.5–60.5].970Fluoroscopy time (min)14.8 [10.6–26.9]14.1 [13.1–23.1].936Complications0 (0.0)0 (0.0)1.000Number of premaps1.0 [1.0–2.0]1.0 [1.0–2.0].775Premap 1 attempt22 (68.8)4 (57.1).666Number of deployments1.0 [1.0–1.0]1.0 [1.0–1.0].688Electrical parameters: premapImpedance (Ω)290.0 [270.0–317.5]270.0 [260.0–310.0].367Sensing (mV)1.3 [1.1–2.5]1.3 [1.1–1.8].971Threshold (V) at 0.4 ms2.5 [1.9–3.0]3.2 [2.9–4.2].026Amplitude (mV)1.4 [0.9–1.9]1.4 [0.8–1.5].461COI (mV)1.8 [1.4–2.1]1.6 [1.1–1.7].168dV/dt-R (V/s)116.0 [76.0–139.5]123.0 [74.0–158.5].706dV/dt-S (V/s)−152.0 [−226.8 to −87.8]−118.0 [−142.5 to −97.5].394dV/dt-J (V/s)161.0 [92.0–202.5]136.0 [78.0–165.5].327Duration (ms)40.0 [36.0–45.0]35.0 [27.5–42.0].200Δ impedance (Ω)40.0 [20.0–50.0]10.0 [−45.0 to 55.0].217Values are median [interquartile range] or n (%).COI = current of injury; dV/dt = first derivative of voltage over time; PCT = pacing capture threshold. Procedural and premapping electrical parameters according to 3-month atrial pacing threshold Values are median [interquartile range] or n (%). COI = current of injury; dV/dt = first derivative of voltage over time; PCT = pacing capture threshold. Temporal changes in electrical parameters according to 3-month atrial pacing threshold. Line graphs show impedance, sensing amplitude, and atrial PCT at premapping, postfixation, postdeployment, postimplant day 1, 1 month, and 3 months. Data are presented as median and interquartile range. PCT = pacing capture threshold. Assessment of commanded electrogram parameters: a conceptual visualization framework. A: Grid-based conceptual schematic for visualizing the R-wave upstroke velocity (dV/dt-R) on a standard programmer display. In our exploratory analysis, steeper upstrokes (illustrated by the green region, with dV/dt-R values of approximately ≥140 V/s shown as a hypothesis-generating reference value) tended to occur in patients with very low chronic PCTs, whereas shallower upstrokes (red region, approximately ≤80 V/s) tended to occur in patients with elevated chronic PCT. The numerical values shown are illustrative reference values for visualization only and are not validated procedural or clinical cutoffs; this panel is intended as a conceptual framework and is not intended to guide procedural or clinical decision making. B: Representative premapping commanded electrograms shown as illustrative examples grouped by chronic outcome. Tracings from patients with very low chronic PCT included a high-amplitude signal (2.3 mV) with a steep upstroke (dV/dt-R 178 V/s) and a preserved-amplitude signal (1.3 mV) with an adequate upstroke (dV/dt-R 123 V/s). Tracings from patients with elevated chronic PCT included a borderline-amplitude signal (1.1 mV) with a reduced upstroke (dV/dt-R 77 V/s) and a low-amplitude signal (0.8 mV) with a slow upstroke (dV/dt-R 48 V/s). All numerical values are provided for visualization only and represent illustrative, hypothesis-generating reference values rather than validated clinical cutoffs; this panel is not intended to guide procedural or clinical decision making. dV/dt = first derivative of voltage over time; PCT = pacing capture threshold. Discussion These findings suggest that atrial leadless pacing may differ from ventricular leadless pacing, in which impedance rise and COI have shown stronger prognostic value.6,7 In this atrial cohort, the premapping pacing threshold itself was the only variable that differed between the favorable and elevated 3-month PCT groups. However, this finding is unlikely to represent an independent predictor: because operators were not blinded to the premap measurements, the premapping threshold directly informed the decision to deploy or acquire an additional premap, so its association with chronic performance is at least partly driven by procedural site selection rather than by a tissue-intrinsic property. Therefore, the premapping threshold should be regarded as a procedural decision marker rather than as an independent biological predictor of chronic atrial pacing performance. Waveform-derived parameters such as cEGM amplitude and dV/dt indices did not discriminate the primary endpoint and were only suggestive in exploratory, hypothesis-generating analyses; the numerical values shown should be interpreted as illustrative reference points rather than as clinically actionable cutoffs and were not shown to add incremental value over the premapping threshold in this cohort. Importantly, the absence of statistical significance for these waveform parameters cannot be interpreted as the absence of association, given the small sample size, limited statistical power, and multiple exploratory comparisons. A physiological rationale specific to atrial leadless pacing is needed because direct extrapolation from ventricular experience may be misleading. Compared with the ventricle, the atrial wall is markedly thinner, more heterogeneous, and frequently affected by age-related fibrosis and atrial cardiomyopathy, all of which may decouple intraprocedural electrical signals from chronic capture behavior.8,9 Engagement of the Aveir AR helix in this thin and remodeled myocardium depends on local tissue integrity for both fixation and stable electrical contact, and modest variations in fibrotic burden, regional wall thickness, or chamber geometry may have a disproportionate effect on chronic threshold that is not necessarily captured by acute waveform morphology or impedance. Right atrial enlargement and tricuspid regurgitation, both more frequent in the elevated PCT group, are markers of adverse atrial remodeling and altered chamber geometry that could plausibly destabilize helix engagement and contribute to higher chronic thresholds.8,9 Together, these atrial-specific considerations support a cautious interpretation of premapping cEGM signals and underscore the need for atrial-targeted, prospectively validated procedural markers rather than direct application of ventricular predictors. Limitations This study was retrospective, single-center, and based on a small cohort of 39 patients, with limited statistical power and multiple exploratory comparisons; therefore, nonsignificant findings cannot be interpreted as the absence of association. Operators were not blinded to the intraprocedural electrical data and used the premapping threshold to inform deployment and repositioning, so the apparent association between the premapping threshold and chronic performance is confounded by operator-driven site selection rather than reflecting an independent biological predictor. Some waveform measurements required off-line image-based analysis, the cohort was underpowered for robust multivariable modeling or for the derivation of definitive procedural cutoffs, and no validation cohort was available. All numerical values for waveform-derived parameters reported in this manuscript are illustrative and hypothesis generating, not validated for clinical use; in particular, these waveform parameters were not shown to provide incremental value beyond the premapping threshold. Accordingly, all findings, including those of the secondary and exploratory analyses, should be interpreted strictly as hypothesis generating, and prospective multicenter studies with prespecified analyses are required before any of these signals can be considered for clinical decision making. Conclusion Premapping atrial pacing threshold was the most readily apparent intraprocedural marker of 3-month atrial pacing performance after leadless atrial pacemaker implantation; however, this association is likely confounded by operator-driven site selection and should not be regarded as an independent predictor. Waveform-derived parameters such as cEGM amplitude and dV/dt indices did not discriminate the primary endpoint and provided only exploratory, hypothesis-generating signals; the numerical values shown are illustrative reference values, not validated cutoffs, and were not demonstrated to add incremental value beyond the premapping threshold. All findings of this small single-center study are exploratory and require prospective multicenter validation before they can inform clinical or procedural decision making. Disclosures K. Yamashita received speaker honoraria and lecture fees from Daiichi Sankyo, Johnson & Johnson/Biosense Webster, Medtronic Japan, Abbott Medical Japan, Japan Lifeline, and Kaneka Medix. The other authors declare no conflicts of interest. Acknowledgments We thank Tatsuo Uchida for technical assistance with the electrophysiological analyses. Funding Sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Authorship All authors attest they meet the current ICMJE criteria for authorship. Patient Consent Because this was a retrospective observational study, an opt-out approach was used in lieu of a written informed consent; patients were notified of the study through a public posting at the institution and were given the opportunity to decline participation, and all patient data were deidentified before analysis. Ethics Statement The research reported in this manuscript adhered to the principles of the Declaration of Helsinki and was approved by the institutional review board of Sendai Kosei Hospital (approval number: 7-46). Footnotes Supplementary data associated with this article can be found in the online version at https://doi.org/10.1016/j.hroo.2026.05.017. Supplementary Data Supplemental Material References Associated Data Supplementary Materials Supplemental Material